Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 12—December 2023
Research

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023

Todd G. SmithComments to Author , Crystal M. Gigante, Nhien T. Wynn, Audrey Matheny, Whitni Davidson, Yong Yang, Rene Edgar Condori, Kyle O’Connell, Lynsey Kovar, Tracie L. Williams, Yon C. Yu, Brett W. Petersen, Nicolle Baird, David Lowe, Yu Li, Panayampalli S. Satheshkumar, and Christina L. Hutson
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (T.G. Smith, C.M. Gigante, N.T. Wynn, A. Matheny, W. Davidson, Y. Yang, R.E. Condori, K. O’Connell, L. Kovar, T.L. Williams, Y.C. Yu, B.W. Petersen, N. Baird, D. Lowe, Y. Li, P.S. Satheshkumar, C.L. Hutson); Deloitte Consulting LLC, Arlington, Virginia, USA (K. O’Connell); Leidos Inc., Reston, Virginia, USA (L. Kovar)

Main Article

Figure 2

Examples of tecovirimat resistance in mpox patients, United States, 2022–2023. Patient samples were sequenced, cultured, and subjected to tecovirimat sensitivity testing in a cytopathic effect assay. A) Different samples from the same patient showed different F13 amino acid substitutions that result in different levels of resistance compared with the wild-type control (MPXV clade IIa, collected in the United States in 2003 [GenBank accession no. ON563414]). B) Samples from the same patient at different times before and after starting tecovirimat treatment in August 2022, showing sensitivity before drug treatment and increasing resistance after drug treatment. Abs570, absorbance at 570 nm.

Figure 2. Examples of tecovirimat resistance in mpox patients, United States, 2022–2023. Patient samples were sequenced, cultured, and subjected to tecovirimat sensitivity testing in a cytopathic effect assay. A) Different samples from the same patient showed different F13 amino acid substitutions that result in different levels of resistance compared with the wild-type control (MPXV clade IIa, collected in the United States in 2003 [GenBank accession no. ON563414]). B) Samples from the same patient at different times before and after starting tecovirimat treatment in August 2022, showing sensitivity before drug treatment and increasing resistance after drug treatment. Abs570, absorbance at 570 nm.

Main Article

Page created: October 18, 2023
Page updated: November 18, 2023
Page reviewed: November 18, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external